India faces a host of biological risk factors. Drawing lessons from the coronavirus pandemic and prior biological disasters, India’s government should pursue new safety protocols and develop new institutions to manage future biological risk.

Biotechnology has unlocked vast potential for improving human life, but the risks it poses mean that multilateral safeguards are due for an update.

For India, the equation is pretty simple: better diplomatic relations between the United States and Iran would let New Delhi deal more smoothly with both countries. A decline in the relationship adversely affects Indian interests.

A Chinese scientist dropped a bombshell in November 2018 when he unveiled the world’s first gene-edited babies. How are other countries, including India, navigating the dizzying array of rewards and risks associated with gene-editing research?

Crucial questions need to be asked with regards to fragmented legal frameworks, unclear regulatory practices ambiguous policy advances and voluntary measures governing gene-editing technologies at national and international levels.

India cannot and will not compete with China in the AI realm—instead it will play to its advantages by becoming a global AI hub for non-Chinese and non-Western markets.